Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2021-04-30 Regulatory Filings
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding a 'Correction Report' (정정신고) for a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details a change in the contract end date. Since this is a specific regulatory disclosure regarding a material contract update that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2021-04-30 Korean
투자판단관련주요경영사항(진행성 또는 전이성 위암 및 위식도접합부암 환자 대상 1차 치료로 캄렐리주맙과 카페시타빈/옥살리플라틴 병용 투여 후 리보세라닙(아파티닙)과 캄렐리주맙 병용투여, 3상 임상시험 계획(IND) 승인 신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from HLB Life Science regarding the submission of an Investigational New Drug (IND) application for a Phase 3 clinical trial. It details the clinical trial design, objectives, and regulatory submission status to the Korean Ministry of Food and Drug Safety (MFDS). Since this is a specific regulatory announcement regarding business operations and clinical trial progress that does not fit into categories like financial reports, dividends, or M&A, it is classified as a Regulatory Filing (RNS).
2021-04-19 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과). It details the approval of financial statements, dividend decisions, and the election of directors (board members). This falls under the category of Declaration of Voting Results & Voting Rights Announcements, as it provides the outcome of the shareholder votes held at the meeting.
2021-03-31 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). This is a standard corporate governance disclosure in South Korea regarding changes to the board of directors. Since it specifically details the appointment of an outside director, it falls under the 'Board/Management Information' category.
2021-03-31 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). This type of filing is a standard regulatory disclosure for insiders and major shareholders to report changes in their holdings. In the provided taxonomy, 'Director's Dealing' (DIRS) is the most appropriate category for reports detailing share transactions or ownership changes by company directors, executives, and major shareholders.
2021-03-26 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically due to a bonus issue/stock split) by a major shareholder (HLB Co., Ltd.) in HLB Life Science Co., Ltd. This type of filing is a mandatory disclosure for significant shareholding changes, which falls under the 'Major Shareholding Notification' category.
2021-03-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.